drugset / Trial / NCT02433678

An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin

NCT02433678

Phase 4 Completed 52 enrolled University at Buffalo Kaleida Health · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a single center, prospective, randomized, placebo -controlled, parallel design and double blind study to evaluate oxidative stress, inflammation and hypertension markers and mediators before and after treatment with dapagliflozin.

Timeline

Start
2015-11
Primary completion
2018-03
Completion
2018-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dapagliflozin Small molecule 10 mg